Comparison between Molbio Diagnostics IPO and RSB Retail India IPO.
Molbio Diagnostics IPO is a Mainboard Bookbuilding IPO proposed to list at BSE, NSE while RSB Retail India IPO is a Mainboard Bookbuilding proposed to list at BSE, NSE.
The total issue size of Molbio Diagnostics IPO is up to ₹0.00 Cr whereas the issue size of the RSB Retail India IPO is up to ₹0.00 Cr. The final issue price of Molbio Diagnostics IPO is and of RSB Retail India IPO is .
| Molbio Diagnostics IPO | RSB Retail India IPO | |
|---|---|---|
| Face Value | ₹1 per share | ₹2 per share |
| Issue Price (Lower) | ||
| Issue Price (Upper) | ||
| Issue Price (Final) | ||
| Discount (Retail) | ||
| Discount (Employee) | ||
| Market Lot Size | ||
| Fresh Issue Size | 0 shares | 0 shares |
| Fresh Issue Size (Amount) | up to ₹200.00 Cr | up to ₹500.00 Cr |
| OFS Issue Size | 1,25,56,000 shares | 2,98,78,946 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
| Issue Size Total | 0 shares | 0 shares |
| Issue Size Total (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
Molbio Diagnostics IPO opens on , while RSB Retail India IPO opens on . The closing date of Molbio Diagnostics IPO and RSB Retail India IPO is , and , respectively.
Molbio Diagnostics IPO P/E ratio is , as compared to RSB Retail India IPO P/E ratio of .
| Molbio Diagnostics IPO | RSB Retail India IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated)Molbio Diagnostics Ltd.'s revenue increased by 22% and profit after tax (PAT) rose by 66% between the financial year ending with March 31, 2025 and March 31, 2024.
| Company Financials (Restated)RSB Retail India Ltd.'s revenue increased by 10% and profit after tax (PAT) rose by 69% between the financial year ending with March 31, 2025 and March 31, 2024.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 46.65 | 100 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 16.20% | 25.83% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 20.98% | 28.95% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 2.35 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹12.29 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 15.23% | 22.85% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Molbio Diagnostics IPO Retail Individual Investors (RII) are offered 0 shares while in RSB Retail India IPO retail investors are offered 0 shares. Qualified Institutional Buyers (QIB) are offered 0 shares in Molbio Diagnostics IPO and 0 shares in RSB Retail India IPO.
| Molbio Diagnostics IPO | RSB Retail India IPO | |
|---|---|---|
| Anchor Investor Reservation | 0 shares | 0 shares |
| Market Maker Reservation | 0 shares | 0 shares |
| QIB | 0 shares | 0 shares |
| NII | 0 shares | 0 shares |
| RII | 0 shares | 0 shares |
| Employee | 0 shares | 0 shares |
| Others | ||
| Total | 0 shares | 0 shares |
Molbio Diagnostics IPO subscribed in total, whereas RSB Retail India IPO subscribed .
